JO
EDVA

John Overdeck’s Endovia Health Sciences, Inc. EDVA Stock Holding History

John Overdeck’s Portfolio EDVA Stock Details EDVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-458
Closed -$208K – 2881
2022
Q1 		$208K Buy
+458
New +$234K ﹤0.01% 2328

Other funds holding EDVA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return
PCM
Parsons Capital Management Providence, Rhode Island $2.21B AUM 28.12% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
TF
TRH Financial North Liberty, Iowa $297M AUM 7.9% 1-Year Est. Return

John Overdeck's EDVA Position: Q2 2022 in Review

John Overdeck sold out of Endovia Health Sciences, Inc. (EDVA) in Q2 2022, closing a stake of 458 shares — an estimated $208K sold.

John Overdeck first reported a position in EDVA in Q1 2022 and held it in 1 quarter. The position peaked at $208K in Q1 2022. 22 funds tracked by Wall St. Rank hold EDVA as of Q2 2022.

  • John Overdeck reported no remaining Endovia Health Sciences, Inc. position as of Q2 2022 after selling out during the quarter.
  • John Overdeck sold 458 Endovia Health Sciences, Inc. shares in Q2 2022, an estimated $208K.
  • John Overdeck first reported a position in Endovia Health Sciences, Inc. in Q1 2022 and held it in 1 quarter.
  • John Overdeck's Endovia Health Sciences, Inc. position peaked at $208K in Q1 2022.
  • 22 funds tracked by Wall St. Rank held Endovia Health Sciences, Inc. as of Q2 2022.

Based on Two Sigma Investments's 13F filing for Q2 2022, filed 15 Aug 2022.